Login to Your Account

Clinic Roundup

Wednesday, April 17, 2013
• Northwest Biotherapeutics Inc., of Bethesda, Md., said its Phase III study testing DCVax personalized immune therapy in glioblastoma multiforme was "adopted" as a national priority trial in the UK.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription